New Search Advanced Search

Results

Your search returned '10' results

• Loxapine inhalation for agitation associated with schizophrenia or bipolar disorder

  Agency: NHSC

  Name: Loxapine inhalation (Staccato loxapine, AZ-004)

  Technology Type: Drug Device

  Patient Indications: People with agitation associated with schizophrenia or bipolar disorder.

  Entered On: August 24 2010

• Afatinib for advanced and/or metastatic non-small cell lung cancer (NSCLC) with EGFR mutation

  Agency: NHSC

  Name: Afatinib (BIBW2992)

  Technology Type: Drug

  Patient Indications: NSCLC with EGFR mutation: locally advanced and/or metastatic – first line.

  Entered On: August 18 2010

• Apixaban for stroke prevention in atrial fibrillation

  Agency: NHSC

  Name: Apixaban (BMS 562247; BMS 562247-0)

  Technology Type: Drug

  Patient Indications: Atrial fibrillation (AF) – prevention of stroke in patients with additional risk factor/s for stroke.

  Entered On: August 18 2010

• Axitinib for advanced and/or metastatic renal cell carcinoma – second line.

  Agency: NHSC

  Name: Axitinib (AG 013736; AG 13736; AG-013736; AG-13,736)

  Technology Type: Drug

  Patient Indications: Renal cell carcinoma (RCC): advanced and/or metastatic – second line; after failure of one prior systemic therapy including sunitinib, bevacizumab with interferon alpha, temsirolimus, or cytokines (interferon alpha or interleukin-2).

  Entered On: August 18 2010

• Bevacizumab with trastuzumab and docetaxel for metastatic HER2 positive breast cancer

  Agency: NHSC

  Name: Bevacizumab (Avastin; anti-VEGF monoclonal antibody; R 435; RG435; rhuMAb-VEGF)

  Technology Type: Drug

  Patient Indications: Breast cancer: metastatic; HER2 positive – first line; in combination with trastuzumab and docetaxel.

  Entered On: August 18 2010

• Oral calcitonin for osteoarthritis (OA) of the knee in men and postmenopausal women – first line

  Agency: NHSC

  Name: Oral calcitonin (oral salmon calcitonin, salmon calcitonin, SMC-021)

  Technology Type: Drug

  Patient Indications: Osteoarthritis (OA) of the knee in men and postmenopausal women – first line; monotherapy or in combination with symptom modifying OA drugs.

  Entered On: August 16 2010

• Vorapaxar for acute coronary syndrome

  Agency: NHSC

  Name: Vorapaxar

  Technology Type: Drug

  Patient Indications: Acute coronary syndrome: unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI) or ST-segment elevation myocardial infarction (STEMI).

  Entered On: August 17 2010

• Erlotinib hydrochloride (Tarceva) for advanced non-small cell lung cancer with activating mutations

  Agency: NHSC

  Name: Erlotinib hydrochloride (Tarceva, CP-358774, OSI-774, R-1415)

  Technology Type: Drug

  Patient Indications: • Non-small cell lung cancer (NSCLC): locally advanced and/or metastatic; activating EGFR mutations – first line.

  Entered On: August 13 2010

• OncoVEX GM-CSF for unresectable metastatic melanoma – first and second line treatment

  Agency: NHSC

  Name: OncoVEX GM-CSF

  Technology Type: Drug

  Patient Indications: Malignant melanoma: unresectable, locally advanced and/or metastatic – first and second line.

  Entered On: August 16 2010

• Taspoglutide for type 2 diabetes mellitus

  Agency: NHSC

  Name: Taspoglutide

  Technology Type: Drug

  Patient Indications: Type 2 diabetes mellitus - in combination with metformin, or metformin and a sulphonylurea or a thiazolidinedione.

  Entered On: August 16 2010